What Carfilnat is?
Carfilzomib is an anti-cancer drug indicated to use as a selective proteasome inhibitor for the treatment of: Multiple Myeloma: Patients who have taken at least two prior therapies including treatment with Lenalidomide and Bortezomib.
What Carfilzomib is?
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.